Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside

Significant progress has been achieved over the last decades in understanding the biology and mechanisms of tumor progression in urothelial carcinoma (UC). Although the therapeutic landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors, advanced UC i...

Full description

Bibliographic Details
Main Authors: Antonio Ungaro, Marcello Tucci, Alessandro Audisio, Lavinia Di Prima, Chiara Pisano, Fabio Turco, Marco Donatello Delcuratolo, Massimo Di Maio, Giorgio Vittorio Scagliotti, Consuelo Buttigliero
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cells
Subjects:
urothelial carcinoma
antibody-drug conjugates
ADC
Enfortumab vedotin
ADC resistance mechanism
Online Access:https://www.mdpi.com/2073-4409/11/5/803

Similar Items

Similar Items